MycRx
Melbourne, Australia· Est.
Australian biotech developing first‑in‑class small‑molecule Myc inhibitors for oncology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian biotech developing first‑in‑class small‑molecule Myc inhibitors for oncology.
Oncology
Technology Platform
Proprietary small‑molecule discovery platform that designs compounds to directly bind Myc’s DNA‑binding domain, disrupting its transcriptional activity.
Opportunities
Successful development of oral Myc inhibitors could address a large unmet need in solid‑tumor oncology and attract partnership or acquisition interest from major pharma.
Risk Factors
Technical challenges of targeting an intrinsically disordered transcription factor and the need for significant funding to advance pre‑clinical candidates into clinical trials.
Competitive Landscape
Differentiates from indirect Myc modulators by aiming for direct inhibition, but competes with large pharma and biotech programs targeting Myc pathways.